380 related articles for article (PubMed ID: 29382394)
21. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
22. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
23. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
[TBL] [Abstract][Full Text] [Related]
25. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
[TBL] [Abstract][Full Text] [Related]
26. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
[TBL] [Abstract][Full Text] [Related]
27. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
28. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
Ohata Y; Tomita Y; Nakayama M; Tamura K; Tanigawara Y
J Infect Chemother; 2011 Dec; 17(6):831-41. PubMed ID: 21773752
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
Kitzes-Cohen R; Farin D; Piva G; De Myttenaere-Bursztein SA
Int J Antimicrob Agents; 2002 Feb; 19(2):105-10. PubMed ID: 11850162
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration.
Sinnollareddy MG; Roberts MS; Lipman J; Peake SL; Roberts JA
J Antimicrob Chemother; 2018 Jun; 73(6):1647-1650. PubMed ID: 29506150
[TBL] [Abstract][Full Text] [Related]
31. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
[TBL] [Abstract][Full Text] [Related]
33. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
[TBL] [Abstract][Full Text] [Related]
34. Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Ordóñez Mejia JL; Roberts MS; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4577-84. PubMed ID: 27185798
[TBL] [Abstract][Full Text] [Related]
35. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
36. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
[TBL] [Abstract][Full Text] [Related]
37. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
[TBL] [Abstract][Full Text] [Related]
38. Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous Hemodiafiltration.
Niibe Y; Suzuki T; Yamazaki S; Suzuki T; Takahashi N; Hattori N; Nakada TA; Oda S; Ishii I
Ther Drug Monit; 2020 Aug; 42(4):588-594. PubMed ID: 32049890
[TBL] [Abstract][Full Text] [Related]
39. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of meropenem in critically ill patients with severe infections.
Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]